Late Lessons, Jensen Huang and AI
Markdown version

LL2-09 hindsight check: The pesticide DBCP and male infertility (Bingham and Monforton; Box 9.2 by Albin), Late lessons from early warnings: science, precaution, innovation (EEA Report No 1/2013), Ch. 9, pp. 203–214#

Checked 25 September 2026. The check covers what bears on the chapter’s claims, evidence, predictions and recommendations. It looks mainly at what happened between publication (January 2013) and September 2026. It also draws on older primary records the chapter could have used but did not: the 1977–79 Federal Register notices, and court rulings from 2009–2011. Page numbers are report pages (PDF page minus 2). All web sources were accessed on 25 September 2026.

Author context. Eula Bingham was the US Assistant Secretary of Labor for Occupational Safety and Health from 1977. She ran the 1977–78 DBCP rulemaking the chapter describes, and the National Peach Council’s letter was addressed to her (pp. 204, 206). The chapter is therefore partly a participant’s account of her own agency’s decision. Several sources come from the plaintiffs’ side of the litigation. The most important is DBCP: The Legacy (Misko, Siegel et al., 1993), which supplies the 1958 Shell memorandum, the Panama semen data and other material. Charles Siegel is one of the lawyers who say they “have represented more than 26,000” DBCP-exposed workers (Siegel & Siegel, Int J Occup Environ Health, 1999). None of this makes the account wrong. It does mean that the regulatory details and the scale-of-harm claims need checking against independent records, which this file does.

Annex 3 note. Not applicable. DBCP was not one of the 2001 report’s case studies. The chapter is new in 2013.

Access note. The web-search quota for this session had run out before this check began. Everything below was verified by fetching primary sources directly: - PubMed abstracts; - full-issue Federal Register scans from govinfo (1977, 1978, 1979); - eCFR, including version history, and the 1997 CFR edition; - CourtListener search results and court PDFs from court websites and CourtListener storage; - the USGS Publications Warehouse, the NTP Report on Carcinogens and the OEHHA document server; - PubChem, used for the EU and IARC classifications; - EUR-Lex (the consolidated EU PIC Regulation), the UN Treaty Collection, the WHO publications page and the French Conseil constitutionnel.

Several sources could not be reached: - NIOSH pages (403; the NIOSH Pocket Guide entry was read through a second fetcher); - ECHA (firewall); - the Environmental Working Group (EWG) tap-water database (403); - the California Water Board’s DBCP page (404); - ILO NORMLEX (403); - the Los Angeles Times archive; - the full text of the 2009 Los Angeles Superior Court fraud rulings.

Where a point depends on a secondary source, the text says so.

Overview#

The chapter’s core narrative holds up and is in places strengthened: early animal warnings, a precautionary limit set below the lowest tested dose, harm found by the workers themselves, fast workplace regulation, continued export, and decades of contamination and litigation. The primary regulatory record from 1977–79, which the chapter barely uses, supports the story of weak scrutiny before 1977 more strongly than the chapter’s own uncited account does. Several specific details are wrong, however. The chapter also left out litigation facts that cut against the plaintiffs and were already public in 2013.

What has been vindicated or strengthened - The pre-1977 regulatory record confirms the neglect. The 1977 EPA review of DBCP (a “rebuttable presumption against registration”, or RPAR) records that FDA’s 1961 review dealt only with bromide residues in food. FDA reviewers made “no comments” on the toxicology. In the 1963 tolerance review an FDA official concluded that “no reproduction test would be required”. No registrant ever submitted a chronic feeding or cancer study before 1977. OSHA’s 1978 preamble adds two points: - the 5 ppm rat result behind the 1 ppm recommendation was not statistically significant; - no federal or consensus exposure standard existed before OSHA’s 1977 emergency standard (pp. 204–205, 210–211). - Human harm below 1 ppm is confirmed by the rulemaking record and the published cohorts. The OSHA standard (29 CFR 1910.1044) is still in force in 2026. Apart from a 2019 edit removing Social Security numbers from records, it is unchanged in substance: a limit of 1 part per billion (ppb), a ban on skin contact, and annual sperm counts (p. 206). - The legacy in groundwater is now better quantified. A July 2026 US Geological Survey (USGS) study of more than 13,000 California public-supply wells projects that DBCP will exceed the legal limit in a shrinking number of wells until about 2080 (range 2048–2109). A 2025 USGS national assessment found DBCP was the only one of 22 tracked pesticides to exceed a human-health benchmark, in a Central Valley well network (p. 210). - Accountability has been as slow and uncertain as the chapter said, and more so. Suits first filed in 1993 and 1997 were still being decided in 2020, 2021, 2025 and 2026. Many plaintiffs’ claims were ended as time-barred or on forum grounds without any hearing on the merits. On 21 September 2026 the Hawai‘i Supreme Court revived one banana worker’s claim more than five decades after his exposure; he had died in 2023. Nicaraguan judgments under that country’s Law 364 were refused recognition in US courts (pp. 209–211). - There is still no international control. DBCP was never listed in Annex III of the Rotterdam Convention on prior informed consent. It is not in the EU’s export-notification list. The US, which signed but never ratified the Convention, still controls exports of unregistered pesticides only through a purchaser’s signed acknowledgement (p. 211).

What was wrong, overstated or omitted - Regulatory details are wrong. - FDA did not “approve and register” DBCP or recommend the 1 ppm limit in 1961 (p. 205). In 1961 Shell and Dow petitioned FDA for food-residue tolerances. EPA’s record lists the registration of Shell’s Nemagon in September 1964. The 1 ppm figure was the published recommendation of the industry toxicologists (Torkelson et al., 1961). - The final 1978 OSHA standard has no 10 ppb 15-minute ceiling (p. 206). OSHA had proposed one and deleted it. - The 1977 EPA action suspended 19 food-crop uses and restricted the rest. All remaining uses except Hawaiian pineapples were suspended only in October 1979, and registration was cancelled in 1985 (p. 207). - The exposure–response numbers are selectively presented. - The published Lathrop data cover 107 exposed men: 13.1% had no sperm and 16.8% had severely low counts, against 2.9% and 0% in 35 controls. The chapter’s figure of “9 of 13” is at best a high-exposure subgroup. - The Magnolia figures in the OSHA record are 47 of 86 exposed men (about 55%), with no local control group. - OSHA also had null or inconclusive results from other plants (Dow Midland, Shell Mobile, Shell Denver), which the chapter does not mention (p. 206). - The scale of harm among plantation workers is still unverified by controlled epidemiology. The largest dataset remains a litigation database of about 26,400 plaintiffs with no control group (Slutsky et al., 1999). A PubMed search in September 2026 found no controlled reproductive study of Central American, African or Philippine applicators published since then (pp. 203, 209). - The litigation account was one-sided even in 2013. It omitted evidence that cuts against the plaintiffs: - a US federal court’s 2009 refusal to recognise a USD 97 million Nicaraguan judgment, affirmed in 2011; - the Ninth Circuit’s 2010 order reprimanding or suspending plaintiffs’ lawyers who kept up an appeal to enforce the USD 489 million judgment the chapter cites, using a document the court called spurious; - the 2009–2010 Los Angeles dismissals of Nicaraguan cases for fraud, which are themselves contested (pp. 209–210). - “First clear example” (p. 203) is contestable. Oligospermia was part of the chlordecone (Kepone) poisoning of chemical workers in 1974–75, reported in 1978. Semen effects in lead-exposed workers were reported in 1975. By 1985 carbon disulfide was also classed as a confirmed male reproductive toxicant; the date of the first reports on it was not verified here. - The endocrine-disruptor link (pp. 203, 211) is analogy, not evidence. DBCP’s established mode of action is direct damage to the sperm-forming cells of the testis, not classic hormone disruption. The wider evidence on falling sperm counts and endocrine disruptors has grown but remains contested.

Still contested or unresolved - Human cancer. Evidence is still “inadequate” (IARC 1999; NTP 2021). The classifications are unchanged since 2013. - High-dose animal tests. Whether they reliably predict effects at low doses remains an open methodological fight, now centred on the “kinetically-derived maximum dose” (KMD) proposal. The chapter’s claim (p. 207) is uncited. - Health effects of today’s low drinking-water levels. These are little studied. One ecological study reports an association in multi-pollutant models only.

Claim-by-claim assessment#

Claim 1: The toxicology available in 1961 was sufficient to require specific warnings, protective equipment and medical surveillance; none was provided. The 1 ppm registration limit sat below the lowest dose tested (5 ppm), with no lower-dose data (p. 205)#

What the chapter says. - By 1958 Shell and Dow had rat data showing testicular effects. - Hine’s report recommended less than 1 ppm and impermeable clothing. A Shell representative called this impractical in “a series of discussions” with FDA. - “In 1961 the US Food and Drug Administration approved and registered DBCP as a pesticide and recommended the exposure limit of 1 ppm.” - USDA accepted Shell’s argument that the 1.7 ppm odour was an adequate warning. - There was no surveillance, and the 1961 evidence was “sufficient” to require warnings, protective equipment and surveillance (pp. 204–205). - The chapter’s own summary says DBCP was “approved for use as a fumigant in 1964” (p. 203), and Table 9.1 says 1961 (p. 212).

Subsequent developments and primary records. - Registration history (1961 vs 1964; FDA vs USDA). EPA’s RPAR notice of 22 September 1977 includes a dated regulatory history (42 FR 48026, 22 Sept 1977, pp. 48028–48029): - On 6 February 1961 Shell and Dow jointly petitioned FDA for residue tolerances on 44 crops, supported by the Torkelson toxicology. “No comments were made by FDA reviewers” on it. - FDA’s 1961 reviews dealt with inorganic bromide residues and judged them safe. USDA “certified usefulness” in April 1961. - The tolerances were proposed in May 1963. In connection with a 1963 request to raise the citrus tolerance, an FDA official (O. G. Fitzhugh) concluded that “no reproduction test would be required”, on the strength of long use of bromides and the presumed absence of DBCP residues in crops. The record prints the memo’s date as “September 6, 1973”, apparently a misprint, since it is listed among the 1963 entries. - The “Application for registration of Shell’s Nemagon” was filed on 16 September 1964, and the registration was issued on 26 September 1964. (Before 1970 pesticide registration was USDA’s job under FIFRA, the federal pesticide law.) - When Dow registered a manufacturing-use product in 1973 and resubmitted the Torkelson study, the file “contains no record of any comment”. “No chronic feeding or oncogenicity studies were submitted by any registrants.”

So the chapter’s statement that FDA “approved and registered DBCP … and recommended the exposure limit of 1 ppm” (p. 205) is not supported. FDA’s 1961 role was food-residue tolerances. The federal registration record EPA cites is dated 1964. The chapter’s “1964” (p. 203) is closer to the record than its “1961” (p. 205; Table 9.1). - Where the 1 ppm figure came from. OSHA’s 1978 preamble is explicit (43 FR 11514, 17 Mar 1978, at 11514 and 11517). The 1 ppm figure was the recommendation of the Torkelson et al. (1961) paper. It rested on rats exposed 50 times to 5 ppm, in which half the animals had testis weights reduced by about 50%. OSHA noted that this result “was not statistically significant due to the large internal variation”, but that it indicated a need for caution. OSHA also found that “no national consensus standard or Federal standard” existed before its 1977 emergency standard. This confirms the chapter’s point that the limit sat below the lowest tested dose, with no lower-dose data. It also supports the digest’s inference that a non-significant 5 ppm result was treated as grounds for a permissive limit rather than for further testing. - The FDA–Shell–Dow “discussions” and USDA’s label reservations. The chapter cites nothing for the discussions and Thrupp (1991) for the USDA part. The EPA regulatory history does not mention either. Neither could be independently verified here. The EPA history’s “no comments” and FDA’s 1963 decision not to require reproduction testing are, if anything, stronger evidence of regulatory inattention than the chapter’s account. - Odour as a warning. Three different “odour thresholds” appear in the records: - 1.7 ppm, the chapter’s figure from Torkelson; - about 180 ppb, OSHA’s estimate in 1978 (43 FR at 11523); - “between 0.01 and 0.03” ppm, which Dow told EPA in 1977.

All three lie at or above the air concentrations later associated with sterility (0.04–0.43 ppm), and 10 to 1,700 times the 1 ppb limit OSHA adopted. The current OSHA standard’s data sheet still tells workers that DBCP cannot be smelled until well above the permissible limit (29 CFR 1910.1044, App. A). The chapter’s conclusion that smell was an inadequate warning holds whichever figure is used. - 1961 norms. In 1961 there was no federal occupational safety law (OSHA dates from 1970). Formal reproductive-toxicity testing guidelines were only being developed in response to thalidomide (Collins, Curr Pharm Des, 2006). By the standards of the time, the absence of reproductive warnings and semen surveillance was not unusual. The chapter’s judgement is still not merely hindsight, for two reasons: - the companies’ own consultant recommended specific controls (under 1 ppm, impermeable clothing, instruments rather than smell); - FDA’s 1963 decision shows the reproductive question was raised and waived.

Verdict: partly held up. The substance (warnings existed, a precautionary limit rested on no low-dose data, and no surveillance followed) is supported and in places strengthened by the 1977–78 federal record. The regulatory specifics are wrong: FDA’s role, the registration date, and the implication that a regulator set the 1 ppm limit.

Implications for weight. The lesson that a limit set below the lowest tested dose is an assumption, not a finding, is well grounded (pp. 205, 210). So is the lesson that regulators deferred to industry framing. The official record shows the regulatory question was framed around food residues, which pushed worker reproductive risk out of scope. That is a stronger and better-documented mechanism than the uncited “discussions” the chapter relies on. Anyone using this chapter should cite the regulatory history from the 1977 EPA record, not from the chapter.

Claim 2: Human sterility occurred below 1 ppm: at Occidental’s Lathrop plant (0.29–0.43 ppm) 9 of 13 workers had no sperm and 4 had low counts; at Dow’s Magnolia plant (0.04–0.4 ppm) half of 106 workers were affected. OSHA’s 1978 standard (1 ppb 8-hour average, 10 ppb over 15 minutes, medical surveillance) was “not effectively challenged” (p. 206)#

Subsequent developments and primary records. - The Lathrop data. - The first published report found azoospermia (no sperm) or oligospermia (low sperm counts) in 14 of 25 men who had not had vasectomies (Whorton et al., Lancet, 17 Dec 1977). - The full NIOSH-funded study covered 107 exposed men and 35 controls. In the exposed men, 13.1% had no sperm, 16.8% severe oligospermia and 15.8% mild oligospermia. In the controls the figures were 2.9%, 0% and 5.7% (Whorton et al., J Occup Med, 1979). - OSHA’s preamble uses the same 107-man figures and adds three details: the air levels (0.29–0.43 ppm 8-hour average), that Lathrop was a formulation plant (Occidental’s Agricultural Chemical Division) handling DBCP since 1957, and that sperm counts worsened with duration of exposure (43 FR 11514, 17 Mar 1978, at 11514 and 11517). - The chapter’s “9 of 13 … and another four” could not be matched to any published figure. If accurate, it describes a high-exposure subgroup, not the plant. - The Magnolia data. OSHA’s record reports 86 exposed Dow employees: 21 (24.2%) had no sperm and 26 (30.2%) were oligospermic, about 55% in all. Air levels were 0.04–0.4 ppm 8-hour average. There was no local control group. The plant had made DBCP only from January 1976 to August 1977 (43 FR at 11518). The chapter’s “50% of the 106 workers examined” roughly matches the proportion but not the denominator. - Evidence the chapter left out. OSHA’s record also contains results that were null or inconclusive: - At Dow’s Midland plant, 249 potentially exposed workers had sperm counts comparable to 77 controls. Exposures there were measured in 1975 at between “none detectable” and 0.17 ppm. - At Shell’s Mobile plant, where production had run for only about a year, rates did not differ from controls. - At Shell’s Denver plant (0.2–0.4 ppm), the results suggested an effect, but OSHA judged that they “cannot be regarded as conclusive”.

OSHA explicitly declined to treat Midland as a no-effect level, given the Lathrop and Magnolia findings. It also noted that skin absorption made air levels an incomplete measure of dose. The harm below 1 ppm is robust at two plants, but the evidence was not uniform. The chapter presents only the positive sites. - The standard itself. - The 1977 emergency standard set 10 ppb (8-hour average) with a 50 ppb 15-minute ceiling. - The November 1977 proposal set 1 ppb with a 10 ppb 15-minute ceiling and a ban on skin exposure. - The final 1978 standard dropped the ceiling. In OSHA’s words, it “has not included the provision for a 15 minute ceiling exposure limit of 10 ppb”, reasoning that the 8-hour limit already constrained short peaks (43 FR at 11515, 11521–11522).

The chapter’s “10 ppb over any 15-minute period” (p. 206) therefore describes the proposal, not the rule. OSHA also stated that the limit was not a “safe” level. It was the level that minimised the cancer and sterility hazards to the greatest extent feasible. The chapter also gives the Federal Register date as 11 March 1978 in the text; the Federal Register issue is dated 17 March 1978. - Status in 2026. 29 CFR 1910.1044 is in force (eCFR, point-in-time 1 September 2026): - a 1 ppb 8-hour limit; - no eye or skin contact; - annual medical examinations including reproductive history, testicle examination, sperm count, and FSH and LH (hormones that rise when the testes are damaged).

The eCFR version history shows only non-substantive changes since 2017, apart from a 2019 amendment removing Social Security numbers from records (eCFR version history; compare the 1997 CFR edition, which already had no ceiling limit). The standard’s scope still excludes “exposure … which results solely from the application and use of DBCP as a pesticide”. Field applicators were never covered by OSHA’s DBCP rule. NIOSH’s current Pocket Guide lists DBCP as a potential occupational carcinogen with the OSHA limit of 0.001 ppm (NIOSH Pocket Guide). - “Not effectively challenged.” No later court challenge or revision was found. The standard has outlived the domestic industry it regulated: EPA’s 1977 record already notes that Dow and Shell had stopped production.

Verdict: held up. The core claim that sterility occurred in production and formulation workers exposed to air levels well below 1 ppm is confirmed by the rulemaking record and the published cohorts. The standard stands. Two corrections apply: the final standard has no 10 ppb ceiling, and the plant-level figures should be those in the OSHA record. The chapter’s omission of the null and inconclusive plants slightly overstates how uniform the evidence was.

Implications for weight. This is one of the best-documented findings in the whole report, and the lesson that harm appeared 12 to 125 times below the lowest animal dose is sound. Two refinements strengthen it rather than weaken it: - Mixed evidence did not stop action. OSHA acted despite null results at some plants and explicitly refused to read a single null study as a safe level. - Jurisdiction split along the supply chain. OSHA’s rule covered manufacture and formulation but not field use (pp. 206–207). Protection was divided by stage of the chain, a structural gap the chapter mentions only in passing.

Claim 3: DBCP testicular damage is often irreversible: no recovery in men exposed more than 120 hours; “mixed” recovery 17 years later. Also the sex-ratio and family-outcome findings (p. 207)#

Subsequent developments. - No new human follow-up since 1995. No study of the California, Arkansas or Israeli cohorts later than the 17-year Israeli reassessment was found. The evidence base is the same as in 2013, but it is more consistent than the chapter’s brief summary suggests: - Israel, 17 years. In 15 production workers, sperm counts recovered within 36–45 months in 3 of 9 men with no sperm and 3 of 6 with low counts, “with no improvement thereafter”. FSH and LH stayed high in the most severely affected (Potashnik & Porath, J Occup Environ Med, 1995). - Israel, 8 years. Recovery occurred only in men whose FSH had stayed normal (Potashnik & Yanai-Inbar, Fertil Steril, 1987). - California, 7 years. Of 44 Lathrop workers reassessed 5–8 years after exposure ended, 2 of 8 men with no sperm produced sperm, and only one had a normal count. There was no improvement among men with low counts. The authors concluded that “permanent destruction of germinal epithelium occurs in most DBCP-sterile persons” (Eaton et al., J Occup Med, 1986). - The “120 hours” threshold could not be confirmed from the abstracts. One Israeli paper reports that 13 men with no sperm all had more than 100 hours of estimated exposure, and that 4 of them later recovered (Goldsmith et al., Arch Environ Health, 1984). That sits uneasily with an absolute cut-off at 120 hours. - The field-worker data point the same way. Some semen samples in the litigation dataset were taken more than ten years after last exposure and still showed damage. California’s Office of Environmental Health Hazard Assessment (OEHHA) cites this as suggesting the effects persist (OEHHA, draft public health goal (PHG) for DBCP, July 2020, p. 10). In rabbits, abnormal sperm persisted 32 weeks after exposure to 1 ppm ended (OEHHA 2020, citing Rao et al., 1982). - Mechanism. Rat studies show that DBCP leaves the stem cells alive but stops them developing into sperm. In one study, hormone suppression partly restored sperm production, which raises the possibility of intervention in humans (Meistrich et al., Reprod Toxicol, 2003; Meistrich et al., Toxicol Sci, 2003). No human trial was found. - Sex ratio and family outcomes. - In the Israeli families, the share of boys among children conceived during exposure was 16.6%, against 52.9% before exposure, rising to 41.4% after fertility returned (Potashnik & Porath 1995; Potashnik et al., Andrologia, 1984). - There was no excess of birth defects or miscarriage among production workers’ families (Potashnik & Phillip, Andrologia, 1988; Goldsmith, Ann N Y Acad Sci, 1997). - The wives of exposed Israeli banana workers did report more miscarriages (19.8% of pregnancies after exposure against 6.6% before; Kharrazi et al., 1980, as summarised by the Hawai‘i Supreme Court, 21 Sept 2026). That study is now expert evidence in live litigation (see Claim 6). - A systematic review rates the evidence that paternal DBCP exposure lowers the proportion of male births as “limited” (Terrell et al., Emerg Health Threats J, 2011). - An ecological study of Fresno County drinking water found no link with sex ratio or birth outcomes (Whorton et al., Int Arch Occup Environ Health, 1989). Those exposures were far lower.

Verdict: held up. Largely irreversible damage in most severely affected men, with partial recovery in a minority within about four years, is consistent across three cohorts and is accepted by regulators (OEHHA 2020). The evidence base has not grown since 1995. The sex-ratio shift rests on very small numbers.

Implications for weight. The lesson that some harms are irreversible, so acting late costs more (pp. 207, 210–211), is well supported for this case. The cohorts are small, typically 15 to 107 men, and relatively short-term. That is a reason to cite the specific studies rather than generalise about “irreversibility”. The sex-ratio finding should be treated as a suggestive signal, not an established effect.

Claim 4: DBCP classed by EPA as a “probable human carcinogen” since 1992 and by IARC as Group 2B since 1999; the (uncited) assertion that high-dose animal tests have been “in very many cases” reliable predictors of hazards at lower human doses (p. 207)#

Subsequent developments. - No reclassification. - IARC’s list still has DBCP in Group 2B (possibly carcinogenic), based on Volume 71 (1999), with “inadequate” evidence in humans (IARC classification via PubChem, CID 7280; IARC list of classifications). - The US National Toxicology Program’s 15th Report on Carcinogens (December 2021) keeps DBCP as “reasonably anticipated to be a human carcinogen”, first listed in 1981. The basis is animal evidence, with tumours at several sites in rats and mice by oral and inhalation routes. IARC reviewed four worker cohorts and one case-control study. Two cohorts showed excess lung cancer, one liver and biliary cancer and one cervical cancer, but with co-exposures, and IARC judged the evidence inadequate (NTP RoC 15th ed., DBCP profile, 2021). - The EU’s harmonised classification (CLP Annex VI, as rendered by PubChem) carries H350 (may cause cancer), H340 (may cause genetic defects) and H360F (may damage fertility) (PubChem). - US EPA’s drinking-water goal (MCLG) for DBCP remains zero (40 CFR 141.50(a)(9)), consistent with its treatment as a probable carcinogen. The enforceable limit (MCL) remains 0.0002 mg/L, i.e. 0.2 µg/L (40 CFR 141.61(c)). - California’s 2020 draft update proposes a 0.003 ppb public health goal, based on animal cancer data, against 0.0017 ppb in 1999. For effects other than cancer it uses male reproductive toxicity in rabbits (OEHHA 2020). Final adoption was not verified. - Human cancer evidence remains thin. - A Dow cohort of 548 men (deaths 1957–1989) showed no overall cancer excess. There was a lung-cancer relative risk of 3.3 in 81 men with at least a year of direct exposure, confounded by smoking (Olsen et al., Am J Ind Med, 1995). - A cohort of 40,959 Costa Rican banana workers had non-significant excesses of testicular and penile cancer, with no DBCP-specific exposure measure (Hofmann et al., Int J Occup Environ Health, 2006; earlier Wesseling et al., Int J Epidemiol, 1996). - A 2005 review found that no human study had shown a significant positive association, and that all were weak (Clark & Snedeker, J Environ Sci Health C, 2005). - No new DBCP cancer epidemiology was found after 2013. As exposed cohorts age and die, the question may never be resolved. - High-dose animal tests: what DBCP shows. The testicular findings in animals were qualitatively predictive. Quantitatively, humans were far more sensitive than rats: harm appeared at 0.04–0.43 ppm, against a rat low point of 5 ppm. Rabbits studied after 1977 were also more sensitive, with a no-effect level of 0.1 ppm and persistent sperm effects at 1 ppm (Rao et al., 1982, as used by OEHHA 2020). For DBCP the lesson is that the species and dose range tested understated human risk. The problem was not that high doses exaggerated it. The 1979 EPA suspension decision already defended animal bioassays for identifying carcinogens and rejected a manufacturer’s attack on the worker epidemiology (44 FR 65135, 9 Nov 1979). - The general debate after 2013. - Mechanistic frameworks such as the “key characteristics of carcinogens” were adopted to reduce reliance on the rodent bioassay alone (Smith et al., Environ Health Perspect, 2016). - Industry-associated toxicologists have argued that top doses above the point where the body’s handling of a chemical saturates, the “kinetically-derived maximum dose” (KMD), produce effects irrelevant to humans (Saghir, Regul Toxicol Pharmacol, 2015). - Scientists at the Dutch public-health institute RIVM replied that the KMD concept “hampers proper hazard assessment” and should be abolished (Heringa et al., Regul Toxicol Pharmacol, 2020).

The dispute is live. The chapter’s sweeping claim that high doses have been reliable predictors “in very many cases” is neither refuted nor supported by a citation.

Verdict: partly held up. The classifications are unchanged and accurately reported. Human cancer evidence is still inadequate 45 years later. The general claim about high-dose testing is an uncited position in a continuing debate. DBCP itself is a case where animal data underestimated, rather than overstated, the human reproductive hazard.

Implications for weight. Use DBCP as evidence that animal signals should not be dismissed because human doses are lower (pp. 207, 210). Do not use it as evidence for the broad claim that high-dose tests are generally reliable. The more defensible lesson from the record is about the choice of species and doses: rats were a relatively insensitive model, and no one looked for lower-dose effects until people were harmed (lesson 2, p. 210).

Claim 5: After US action in 1977–79, DBCP was still exported and used on banana plantations in Central America and the Philippines until 1985–86, and sold to the Ivory Coast in 1977–80; “tens of thousands” of plantation workers “allegedly” suffered reproductive harm (pp. 203, 207–209)#

Subsequent developments. - Use abroad is not in dispute. Court records since 2013 treat exposure on plantations as a factual premise of the litigation, and defendants have made admissions. - The putative Texas class covered all persons exposed to DBCP between 1965 and 1990 in 25 countries (Marquinez v. Dow, Del. Supreme Court, 15 Mar 2018). - In interrogatory answers quoted by the Hawai‘i Supreme Court, Del Monte confirmed that its Costa Rican subsidiary applied DBCP on its farms in 1970–73, twice a year, at roughly 3.6–7.7 gallons per acre per year (Patrickson v. Dow, Haw., 21 Sept 2026). - The chapter’s end dates (1985 in Central America, about 1986 in the Philippines) were not independently re-verified. - The scale of harm still rests on litigation-derived data. - The largest dataset remains the Slutsky et al. analysis of about 26,400 male plaintiffs in 12 countries, compiled by attorneys from interrogatories. After a median of three years’ exposure, 64.3% had no sperm or low counts, rising to 90.1% in the Philippines. The study had no comparison group, and the men were selected by litigation (Slutsky et al., Int J Occup Environ Health, 1999). - Costa Rica’s documented toll was about 1,500 sterilised workers by 1991 (Thrupp, Int J Health Serv, 1991). - A PubMed search in September 2026 found no controlled epidemiological study of reproductive outcomes in Central American, African or Philippine DBCP applicators published since 1999. Later banana-worker studies address cancer or mortality without DBCP-specific exposure measures (Hofmann et al., 2006). - OEHHA’s 2020 review treats the Slutsky data as evidence at face value (OEHHA 2020, pp. 10–11). - Support for plausibility. - Before the US bans, California applicators showed depressed sperm counts and raised hormone levels (Glass et al., 1979, as summarised by Goldsmith 1997). - Israeli banana workers’ families reported more miscarriages (Kharrazi et al., 1980). - Goldsmith noted that “patterns of effects … in production workers and in applicators … may differ”. - Official compensation in Costa Rica. Under Costa Rica’s Law 8130 the national insurer paid compensation to affected workers outside the workers’ compensation scheme. One plaintiff received ₡683,000 in 2006 (Patrickson v. Dole, Haw. Ct. App., 22 Sept 2025). This implies an administrative acceptance of claims by that state. The number of beneficiaries was not found.

Verdict: partly held up. The export and use after the US bans are well established and uncontested in court. The scale of reproductive harm, “tens of thousands”, remains allegation-grade. It is plausible given the production-worker and applicator evidence, but it has never been measured with a comparison group. The chapter’s own “allegedly” was the right word, and nothing since has removed the need for it.

Implications for weight. The lesson that banning use at home while allowing export moves the hazard elsewhere is strong on the facts of export and use (pp. 207–209, 211). Any quantitative statement about harm abroad should be flagged as resting on litigation data. That gap is itself a finding: when harm falls on workers abroad, nobody builds the evidence base. What exists is assembled for litigation, which makes it easy to contest.

Claim 6: Compensation came about 20 years after the firms knew of the risk: USD 20m for 1,000 workers (1992), USD 41m for 26,000 (1997, about USD 1,500 each), a USD 489m Nicaraguan judgment (2002), USD 300k from Amvac (2007). “Tens of thousands” of suits were still pending in 2013, with facts contested (pp. 209–210)#

Subsequent developments. - Nicaraguan (Law 364) judgments were not enforced in the US. This was already known before 2013 and is omitted by the chapter. - In Osorio v. Dow, a Florida federal court refused to recognise a Nicaraguan judgment of over USD 97 million for 150 workers. The Eleventh Circuit affirmed, holding that the Nicaraguan court lacked jurisdiction, that its procedures were incompatible with due process, and that recognition would be repugnant to Florida public policy. It declined to rule that Nicaragua as a whole lacks impartial tribunals. It also stressed that nothing in its ruling bars litigating the workers’ injury claims on the merits (Osorio v. Dow Chemical, 11th Cir., 25 Mar 2011, 635 F.3d 1277). - The USD 489 million judgment the chapter cites was for 466 plaintiffs in Franco. Its enforcement failed in district court. The plaintiffs’ lawyers kept up an appeal after they knew the document offered as evidence of the judgment was “spurious”. They had repeatedly misstated that a Nicaraguan writ named Dole Food Company as a judgment debtor. In 2010 the Ninth Circuit formally reprimanded Thomas Girardi and suspended Walter Lack and Paul Traina from practice before that court for six months (In re Girardi, 9th Cir., 13 July 2010, 611 F.3d 1027). - The same ruling records that Law 364 required a defendant to post a USD 100,000 bond to appear. - The Los Angeles fraud findings. The first DBCP case to reach trial, in 2007, produced a USD 5 million verdict for six Nicaraguan workers, later reduced to USD 2.3 million. In 2010 Dole obtained dismissal of that and other Nicaraguan cases on allegations of widespread fraud by plaintiffs, lawyers and judges (Boix & Bohme, Int J Occup Environ Health, 2012). Those authors, who are sympathetic to the plaintiffs, argue that many of the accused never had a chance to answer, and that defendants’ conduct was also questionable. The underlying Superior Court rulings (Judge Victoria Chaney, 2009–2010) could not be retrieved, so their exact findings are not verified here. The chapter mentions none of this. Its Box 9.2 gives Dole’s position one clause. - After 2013: litigation ended mostly on procedure, not merits. - Delaware. The Delaware Supreme Court recognised cross-jurisdictional tolling, which lets a failed class action in another state pause the limitations clock (Dow v. Blanco, 10 June 2013, 67 A.3d 392). In 2018 it held that tolling ran until the Texas state court denied class certification on 3 June 2010. On that view the federal Delaware claims, filed in 2012, were within time (Marquinez v. Dow, 15 Mar 2018, 183 A.3d 704). - Third Circuit. Sitting en banc, the court vacated the dismissal of Latin American plaintiffs’ cases under the “first-filed” rule. It said that a result in which “no court will ever reach the merits” more than twenty years after the litigation began was “untenable” (Chavez v. Dole, 3d Cir. en banc, 2 Sept 2016, 836 F.3d 205). - Chaverri. Other plaintiffs in the Delaware state courts lost: their 2013 dismissal was left in place. The dissent observed that these plaintiffs, “despite twenty-seven years of litigation, will never have their case heard on the merits” (Chaverri v. Dole, Del., 12 Jan 2021). - Claims against Occidental. These were transferred to New York and held time-barred. New York’s highest court ruled, 4–3, that the 1995 Texas dismissal on forum grounds ended tolling (Chavez v. Occidental, N.Y. Ct. App., 20 Oct 2020; 2d Cir., 6 Aug 2021, 8 F.4th 91). - The federal Delaware Marquinez case (filed 31 May 2012) was still open, with a docket entry on 4 May 2026 (CourtListener docket). - Hawai‘i. - A case first filed in 1997 was held timely in 2015 (Patrickson v. Dole, Haw., 21 Oct 2015, 137 Haw. 217). - In 2025 the appeals court vacated summary judgments, including a ruling that a Costa Rican state compensation release barred suit (Haw. Ct. App., 22 Sept 2025). - On 21 September 2026 the Hawai‘i Supreme Court adopted a three-step test for causation in toxic-tort cases from the Restatement (Third) of Torts: exposure, general causation, specific causation. It revived a claim by a worker who had never handled DBCP but had slept in chemical warehouses on the farms, and who died in November 2023 (Patrickson v. Dow, Haw., 21 Sept 2026). - The number of pending claims after 2013 could not be established. The procedural record suggests the pool shrank sharply through limitation and forum rulings, rather than through decisions on the merits.

Verdict: strengthened, as to the lesson that compensation through the courts is slow, costly and uncertain (p. 211). Thirteen years on, cases filed in 1993 and 1997 were still being decided, and many claimants were barred without any assessment of the merits. The chapter’s account of the compensation record is incomplete, however. It omits the non-enforcement of the Nicaraguan judgments and the disciplinary and fraud findings. Those facts complicate the picture of simple corporate evasion.

Implications for weight. The lesson about litigation as a slow, costly route to disclosure and redress (pp. 209–211) is sound and, if anything, understated. The chapter should not be relied on as a balanced record of the litigation. Two features of “late accountability” matter for any lens built on this case: - Procedural doctrines decided outcomes. Forum non conveniens (sending a case to another country’s courts), limitation periods and the recognition of foreign judgments decided most claims, not the science. - The claims process attracted misconduct on the plaintiffs’ side too. That misconduct then became a defence.

Claim 7: DBCP persists in groundwater, possibly for more than a century; in 2010 it was detected in 254 of 1,312 California wells (0.01–1.7 ppb against a 0.2 ppb limit); the share of wells above the limit fell from 49% to 25% between 1986 and 2009; according to EWG, tap water for over 4 million Californians exceeds “health limits” (p. 210)#

Subsequent developments. - The USGS statewide assessment of 2026. Data from more than 13,000 public-supply wells (1980–2022) show: - DBCP detected in 9% of public-supply wells statewide since 2010, 21% in the San Joaquin Valley and 13% in the upper Santa Ana River watershed; - about 70% of wells with decreasing concentrations; - increases more common in deeper wells, as the contamination front moves downward.

With a 38-year degradation half-life, the model projects concentrations above the legal limit in a declining number of wells “until approximately 2080 (range: 2048-2109)”, longest in the San Joaquin Valley (Jurgens et al., Sci Total Environ, online 22 July 2026). That is roughly 70 to 130 years after the 1979 suspension, consistent with the chapter’s “over a century”. - The USGS national trend assessment of 2025. Of 22 pesticides tracked since 1993, DBCP was the only one to exceed a human-health benchmark, and it did so in every decade. This was in the one network where it was analysed, in the Central Valley. Exceedances fell “from 50 percent to 15 percent of the samples between 1993 and 2023” (USGS SIR 2025-5081, 26 Sept 2025). The abstract gives the limit as “2 micrograms per liter”; this appears to be a slip for 0.2 µg/L. - Domestic wells. USGS surveys of the state’s groundwater programme (GAMA) list DBCP among the few organic contaminants exceeding health benchmarks in the aquifers used by private domestic wells in the northern San Joaquin Valley (USGS SIR 2023-5049, 5 June 2023) and in Kern County (USGS SIR 2026-5012, 19 May 2026). - State data. OEHHA reports more than 700 detections of DBCP in California public-supply wells in the three years to May 2018, 92% of them in the Central Valley, with a maximum of 1.6 µg/L, eight times the state limit. Those data are raw well water, not necessarily water delivered to customers (OEHHA 2020, p. 1). - Standards. - The federal limit (MCL) is unchanged at 0.2 µg/L (40 CFR 141.61(c)). - OEHHA’s 2020 draft sets its health goal at 0.003 ppb, 67 times below the legal limit. - Health significance at current levels. One California study linked 13 drinking-water contaminants to birth records. DBCP was associated with hypertensive disorders of pregnancy only in multi-pollutant models, not in the robust single-pollutant results (Padula et al., Environ Epidemiol, 2021). Older Fresno studies found no link with stomach cancer, leukaemia or birth outcomes (Wong et al., Br J Ind Med, 1989; Whorton et al., 1989). The health goals rest on animal data. - Treatment and cost recovery. Granular activated carbon remains the standard treatment. EPA researchers have developed a way to regenerate the spent carbon by alkaline hydrolysis (Crincoli & Huling, Chemosphere, 2023). No post-2013 published court opinions on utility cost recovery for DBCP were found on CourtListener. Treatment cost figures were not found. - The EWG figure (over 4 million Californians above “health limits”) could not be re-checked because the EWG site was blocked. It compares tap water against health goals, not legal limits, and is advocacy-sourced.

Verdict: strengthened. Persistence over the long term, possibly more than a century, is now supported by a USGS model based on groundwater age. So are ongoing exceedances in 2023, 45 years after the ban. The chapter’s reported decline in exceedances also continues. The health significance of today’s concentrations remains weakly studied.

Implications for weight. The lesson that persistence creates a liability lasting generations (pp. 210–211) is among the chapter’s best supported. The warning about persistence in soil and water went unheeded for years (lesson 10, p. 211). In fact it was the discovery of DBCP in California wells in 1979 that helped trigger EPA’s final suspension of remaining uses (44 FR 65135, 9 Nov 1979). The claim is about presence and exceedance of standards. Claims about disease burden from current drinking-water exposure should not be drawn from it.

Claim 8: National DBCP standards were not transferred into international standards to protect workers exposed through global trade (p. 211)#

Subsequent developments. - Rotterdam Convention. The Convention on prior informed consent, the main treaty on trade in hazardous pesticides (in force 2004), now lists 57 chemicals in Annex III (pic.int, Annex III page). The chemical-by-chemical list could not be read from pic.int, which loads it dynamically. A secondary listing (Wikipedia, drawn from pic.int in 2020) includes the related fumigant EDB but not DBCP (Wikipedia, “Rotterdam Convention”). The candidate lists there do not include it either. - EU export controls. The consolidated EU regulation on exporting hazardous chemicals (PIC Regulation 649/2012, version of 1 March 2025) does not contain DBCP (CAS 96-12-8) in any annex. That includes the list requiring export notification and the export-ban list, although EDB is listed (EUR-Lex, consolidated Regulation 649/2012). - US. The US signed the Rotterdam Convention on 11 September 1998 but has not ratified it (UN Treaty Collection). US law still lets unregistered pesticides be exported, provided the foreign purchaser signs a statement acknowledging the product is not registered in the US and a copy goes to the importing government (40 CFR 168.75). - Historical nuance the chapter omits. OSHA’s 1978 preamble records that the ILO’s hazard alert system spread the 1977 findings. Japan, Mexico, Israel, the Netherlands, Finland and Sweden, none of which had known of the sterility effect, all suspended use (43 FR 11514, at 11514). International transfer of information did work for some countries in 1977. It did not reach, or did not change practice on, plantations supplied by US firms and their contract partners. - The wider issue continues without DBCP. Pressure against exporting pesticides banned at home has grown. In 2020 France’s Constitutional Council upheld a French law banning, from 2022, the production and export of pesticides containing substances not approved in the EU. It ruled that environmental protection can justify limits on freedom of enterprise (Conseil constitutionnel, Décision n° 2019-823 QPC, 31 Jan 2020).

Verdict: held up. DBCP was never brought under any binding international trade-control regime, and the US export regime remains one of acknowledgement, not prohibition. Because DBCP has long left international commerce, this is now mostly of historical and structural interest.

Implications for weight. The lesson that national standards do not travel with traded products (p. 211) holds, and the mechanism it names remains current: controls that stop at the border and rely on purchaser acknowledgement. The ILO episode refines it. Sharing information worked where importing governments could act on it. It failed where the risk ran through private supply contracts and weak regulation where the product was used.

Claim 9: The DBCP lessons are “very relevant” to endocrine-disrupting substances, which “seem to be playing a role” in reproductive ill health in humans and wildlife, and to rising reproductive disease (pp. 203, 211)#

Subsequent developments. - DBCP’s mechanism. The best-characterised mechanism is direct damage to the sperm-forming cells. Treated rats had high gonadotropins and high testosterone inside the testis, so the failure was “not … a result of lack of these hormones” (Meistrich et al., 2003). One review lists DBCP among pesticides that inhibit the enzymes that make testosterone (Ye et al., Molecules, 2011). DBCP is not a typical endocrine disruptor. The chapter’s summary line that it is “one of many examples supporting” concern about endocrine disruptors (p. 203) goes further than the case supports. The conclusion’s claim that its lessons are relevant (p. 211) is defensible as analogy about how warnings are handled. - Endocrine-disruptor assessments. - The WHO/UNEP State of the Science of Endocrine Disrupting Chemicals 2012, cited as “in press”, was published in early 2013 (WHO). - It drew a detailed critique from authors mostly at the consultancies Exponent and Gradient, who said it inferred causation from trends and ignored dose (Lamb et al., Regul Toxicol Pharmacol, 2014). - The report’s authors replied that the critique was “manufacturing doubt” (Bergman et al., Regul Toxicol Pharmacol, 2015). - The Endocrine Society’s second scientific statement (2015) reported strengthened evidence on male reproduction and other endpoints (Gore et al., Endocr Rev, 2015). - Regulation. The EU adopted scientific criteria for identifying endocrine disruptors: - for biocides, Delegated Regulation (EU) 2017/2100; - for plant protection products, Regulation (EU) 2018/605; - and, in 2023, new endocrine-disruptor hazard classes in its chemical classification law (Delegated Regulation (EU) 2023/707). These texts were not re-fetched in this session (EUR-Lex was rate-limiting); the dates are from the regulations’ titles.

The precautionary regulatory turn the chapter advocated has happened in the EU for endocrine disruptors as a class. - Sperm-count trends are contested. - Meta-regressions by Levine and colleagues report a 51.6% fall in mean sperm concentration among men not selected for fertility, 1973–2018, with the decline accelerating after 2000 (Levine et al., Hum Reprod Update, 2017; 2023). - Another global review also found declines (Luo et al., J Assist Reprod Genet, 2023). - But a 2023 meta-regression of US and Western European data from 1993–2018 found no significant trend (Cipriani et al., Andrology, 2023). - A “biovariability” critique argues that the decline hypothesis misreads normal variation (Boulicault et al., Hum Fertil, 2022). - An Irish clinic series of 15,413 men from 2008 to 2023 found sperm concentration rising (Nolan et al., Andrology, 2026). - Testicular cancer. Incidence has risen for decades in many countries. It is now levelling off in some high-incidence countries (Denmark, the UK) and rising in others, without a settled cause (Gurney et al., Eur Urol, 2019).

Verdict: contested. Regulators have acted on concern about endocrine disruptors, and evidence on some chemicals has grown. Whether male reproductive health is declining at population level, and how much endocrine disruptors contribute, remain disputed. DBCP gives little direct evidence either way.

Implications for weight. The DBCP case should carry weight as a precedent for how early reproductive warnings were handled: late surveillance, reliance on reassurance, the harmed noticing first (p. 211). It should not be used as evidence for the claim that endocrine disruptors are driving trends in reproductive disease. That claim needs its own evidence base (see also LL2-10 on BPA and LL2-13 on ethinyl oestradiol).

Claim 10: DBCP is “the first clear example of reproductive damage to workers who manufactured and used a synthetic chemical” (p. 203)#

Subsequent developments. - Kepone (chlordecone). From March 1974 to July 1975, 76 of 133 workers at a Kepone pesticide plant in Hopewell, Virginia, developed an illness. Its features included tremor, weight loss, abnormal eye movements, pain and oligospermia (Cannon et al., Am J Epidemiol, 1978; Reich & Spong, Int J Health Serv, 1983). Reproductive damage in workers making a synthetic pesticide was thus documented before DBCP. But it was one feature of a mainly neurological poisoning, not the defining harm. - Other agents. A 1985 review classed four agents as having “confirmed” adverse effects on male reproduction: carbon disulfide, DBCP, lead and oral contraceptives (in manufacturing workers). It rated chlordecone “inconclusive” (Schrag & Dixon, Annu Rev Pharmacol Toxicol, 1985). Carbon disulfide is a manufactured industrial chemical; when its effects on semen were first reported was not verified here. NIOSH authors write that male-mediated reproductive harm was not “firmly established” until Lancranjan’s 1975 study of lead-exposed workers and Whorton’s 1977 DBCP study (Schrader & Marlow, Asian J Androl, 2014). - Standing of DBCP. Reviewers consistently treat DBCP as the landmark or “sentinel” case. It had a “seminal role” (Goldsmith 1997) and was “the sentinel event” (Teitelbaum, Int J Occup Environ Health, 1999).

Verdict: partly held up. DBCP is widely recognised as the defining case. In it, infertility was the primary, severe, exposure-related and largely irreversible harm, found in both manufacturing and application workers, and it prompted immediate regulation. “First” is not strictly accurate. Kepone oligospermia (1974–75) and the 1975 lead study came earlier. Carbon disulfide may also have come earlier, but that was not verified here.

Implications for weight. Minor for the substantive lessons. The priority claim should be softened to “the landmark” or “the first widely recognised” case. The Kepone parallel is useful in its own right: two pesticide-worker disasters in 1974–77 were found by clinicians and workers, not by regulators’ surveillance.

Cross-cutting observations for using this section as a lens#

These are stated in technology-neutral terms and tied to page references. They combine the chapter with the primary record gathered above.

  1. Framing the regulatory question decides what is tested (pp. 204–205, 210–211). The 1961–63 federal review asked whether bromide residues in food were safe, and concluded that a reproduction test was unnecessary. Worker reproductive risk fell outside every regulator’s question until 1977. Mechanism: a hazard can go unexamined because the assessment is framed around a different exposure pathway, even when the relevant data are in the file.
  2. Jurisdiction split along the supply chain (pp. 206–209, 211). OSHA regulated manufacture and formulation, and its standard excludes field application. EPA regulated field use in phases (1977, 1979, 1985). Nobody regulated use abroad. Mechanism: protection is only as continuous as the chain of jurisdictions. Gaps open where the product changes hands, at the formulator, the grower, and the border.
  3. Decisive evidence came from the most exposed, organised sites; null sites did not stop action (p. 206). Lathrop and Magnolia were positive. Midland and Mobile were null or unclear. OSHA refused to treat a single null study as a safe level. Mechanism: heterogeneous early evidence is normal. Whether regulators wait for consistency or act on the strongest credible signal determines timing.
  4. “Rapid action” was rapid only in part (pp. 206–207). OSHA’s emergency standard came about two and a half weeks after the union’s petition (23 August to 9 September 1977). But EPA’s 1977 action suspended only 19 food-crop uses. Remaining uses were suspended in 1979, after groundwater contamination was found, and registration was cancelled in 1985. Exports went on (pp. 207–209). Mechanism: a clear endpoint and organised workers can speed action at the point of production, while action along the rest of the chain lags.
  5. Sensory or proxy warnings were set far above protective levels (p. 205). Every odour threshold on record (0.01–1.7 ppm) exceeds the eventual 1 ppb limit by 10 to 1,700 times, and several overlap the air levels at which men became sterile. Mechanism: when the warning signal is calibrated to what is easy to detect, not to the level where harm starts, it gives false reassurance.
  6. Relying on proof after the fact moves the burden onto the harmed, and procedure decides (pp. 209–211). Forum non conveniens, limitation periods, recognition of foreign judgments, and fraud allegations on both sides decided most outcomes over more than 30 years. Claimants died while their cases were pending. Mechanism: when accountability is left to litigation, the rules on where and when claims can be brought, not the science, determine who is compensated.
  7. Evidence abroad is litigation-shaped (pp. 203, 209). The main dataset on applicator harm was compiled by plaintiffs’ attorneys, and no controlled study followed. Mechanism: when harm falls on people outside the jurisdiction that produced the hazard, no public institution builds the evidence base. What exists is contestable because of how it was made.
  8. Persistence turns a regulatory decision into a multi-generational liability (p. 210). Exceedances in groundwater are projected to continue until about 2080 (range 2048–2109). Mechanism: for persistent agents, stopping use starts a long tail rather than ending the problem. Monitoring and treatment costs accrue for decades, to people who never used the product.
  9. Analogy should not be presented as evidence (pp. 203, 211). Presenting DBCP as “supporting” concern about endocrine disruptors conflates a lesson about process with evidence about a different mechanism. Mechanism: a vivid case can lend unearned evidential weight to a broader hypothesis. Keeping “how warnings were handled” separate from “what this proves about other agents” protects both.

Sources#

Primary regulatory records (US) - US EPA, “Dibromochloropropane (DBCP): Notice of rebuttable presumption against registration and continued registration of pesticide products”, 42 Fed. Reg. 48026 (22 Sept 1977). https://www.govinfo.gov/content/pkg/FR-1977-09-22/pdf/FR-1977-09-22.pdf - US OSHA, “Occupational exposure to 1,2-dibromo-3-chloropropane (DBCP): Final standard”, 43 Fed. Reg. 11514 (17 Mar 1978). https://www.govinfo.gov/content/pkg/FR-1978-03-17/pdf/FR-1978-03-17.pdf - US EPA, “Dibromochloropropane (DBCP); Suspension order and notice of intent to cancel”, 44 Fed. Reg. 65135 (9 Nov 1979). https://www.govinfo.gov/content/pkg/FR-1979-11-09/pdf/FR-1979-11-09.pdf - 29 CFR 1910.1044, 1,2-dibromo-3-chloropropane (eCFR, current as of Sept 2026). https://www.ecfr.gov/current/title-29/subtitle-B/chapter-XVII/part-1910/subpart-Z/section-1910.1044 ; version history: https://www.ecfr.gov/api/versioner/v1/versions/title-29.json?part=1910&section=1910.1044 ; 1997 CFR edition: https://www.govinfo.gov/link/cfr/29/1910?sectionnum=1044&year=1997&link-type=pdf - NIOSH Pocket Guide to Chemical Hazards, 1,2-Dibromo-3-chloropropane. https://www.cdc.gov/niosh/npg/npgd0184.html - 40 CFR 141.50 (MCLGs) and 141.61 (MCLs). https://www.ecfr.gov/current/title-40/chapter-I/subchapter-D/part-141/subpart-F/section-141.50 ; https://www.ecfr.gov/current/title-40/chapter-I/subchapter-D/part-141/subpart-G/section-141.61 - 40 CFR 168.75, Procedures for exporting unregistered pesticides. https://www.ecfr.gov/current/title-40/chapter-I/subchapter-E/part-168/subpart-D/section-168.75

Hazard classifications and assessments - National Toxicology Program, Report on Carcinogens, 15th ed. (21 Dec 2021), profile: 1,2-Dibromo-3-chloropropane. https://ntp.niehs.nih.gov/sites/default/files/ntp/roc/content/profiles/dibromochloropropane.pdf - IARC, List of classifications (DBCP Group 2B; Vol. 71, 1999). https://monographs.iarc.who.int/list-of-classifications (read via PubChem) - PubChem, 1,2-Dibromo-3-chloropropane (CID 7280): GHS/CLP and carcinogen classification annotations. https://pubchem.ncbi.nlm.nih.gov/compound/7280 - OEHHA (California), Public Health Goal for 1,2-Dibromo-3-Chloropropane in Drinking Water, second public review draft (July 2020). https://oehha.ca.gov/media/downloads/water/chemicals/phg/dbcpphg071720.pdf - WHO/UNEP, State of the Science of Endocrine Disrupting Chemicals 2012 (published 2013). https://www.who.int/publications/i/item/9789241505031

EU and international instruments - Regulation (EU) No 649/2012 (PIC Regulation), consolidated version of 1 Mar 2025. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02012R0649-20250301 - Commission Delegated Regulation (EU) 2017/2100 (ED criteria, biocides). https://eur-lex.europa.eu/eli/reg_del/2017/2100/oj - Commission Regulation (EU) 2018/605 (ED criteria, plant protection products). https://eur-lex.europa.eu/eli/reg/2018/605/oj - Commission Delegated Regulation (EU) 2023/707 (new CLP hazard classes including endocrine disruption). https://eur-lex.europa.eu/eli/reg_del/2023/707/oj - Rotterdam Convention, Annex III chemicals page. https://www.pic.int/TheConvention/Chemicals/AnnexIIIChemicals/tabid/1132/language/en-US/Default.aspx - Wikipedia, “Rotterdam Convention” (Annex III list, drawn from pic.int, accessed 25 Sept 2026; secondary). https://en.wikipedia.org/wiki/Rotterdam_Convention - UN Treaty Collection, Rotterdam Convention status (chapter XXVII-14). https://treaties.un.org/Pages/ViewDetails.aspx?src=TREATY&mtdsg_no=XXVII-14&chapter=27&clang=_en - Conseil constitutionnel, Décision n° 2019-823 QPC (31 Jan 2020). https://www.conseil-constitutionnel.fr/decision/2020/2019823QPC.htm

Court decisions and dockets - Patrickson v. Dow Chemical Co. and Del Monte Fresh Produce N.A., SCWC-22-0000687 (Haw., 21 Sept 2026). https://www.courts.state.hi.us/wp-content/uploads/2026/09/SCWC-22-0000687.pdf - Patrickson v. Dole Food Co., CAAP-22-0000687 (Haw. Ct. App., 22 Sept 2025). https://www.courts.state.hi.us/wp-content/uploads/2025/09/CAAP-22-0000687mop.pdf - Patrickson v. Dole Food Co., 137 Haw. 217 (Haw., 21 Oct 2015). http://www.courts.state.hi.us/docs/opin_ord/sct/2015/October/SCWC-30700.pdf - Dow Chemical Corp. v. Blanco, 67 A.3d 392 (Del., 10 June 2013). https://www.courtlistener.com/opinion/5146577/dow-chemical-corp-v-blanco/ - Chavez v. Dole Food Co., 836 F.3d 205 (3d Cir. en banc, 2 Sept 2016). http://www2.ca3.uscourts.gov/opinarch/134144p1.pdf - Marquinez v. Dow Chemical Co., 183 A.3d 704 (Del., 15 Mar 2018). https://courts.delaware.gov/Opinions/Download.aspx?id=270240 - Chaverri v. Dole Food Co., 220 A.3d 913 (Del. Super., 8 Nov 2019). https://courts.delaware.gov/Opinions/Download.aspx?id=297700 - Chaverri v. Dole Food Co. (Del., 12 Jan 2021). https://courts.delaware.gov/Opinions/Download.aspx?id=315370 - Chavez v. Occidental Chemical Corp., 35 N.Y.3d 492 (N.Y., 20 Oct 2020). http://www.nycourts.gov/ctapps/Decisions/2020/Oct20/39opn20-Decision.pdf - Chavez v. Occidental Chemical Corp., 8 F.4th 91 (2d Cir., 6 Aug 2021). https://www.courtlistener.com/opinion/4905875/tobias-bermudez-chavez-v-occidental-chemical-corp/ - Marquinez v. Dole Food Co., D. Del. (filed 31 May 2012; docket activity 4 May 2026). https://www.courtlistener.com/docket/73296884/marquinez-v-dole-food-company-inc/ - Osorio v. Dow Chemical Co., 635 F.3d 1277 (11th Cir., 25 Mar 2011). http://media.ca11.uscourts.gov/opinions/pub/files/201011143.pdf - In re Girardi, 611 F.3d 1027 (9th Cir., 13 July 2010). http://www.ca9.uscourts.gov/datastore/opinions/2010/07/13/08-80090.pdf

Groundwater monitoring and treatment - Jurgens BC, Wright MT, Faulkner K, et al., “Legacy of the fumigant 1,2-dibromo-3-chloropropane (DBCP) in California groundwater”, Sci Total Environ 1048:182030 (online 22 July 2026). https://doi.org/10.1016/j.scitotenv.2026.182030 - USGS, Multidecadal change in pesticide concentrations relative to human health benchmarks in the Nation’s groundwater, SIR 2025-5081 (26 Sept 2025). https://doi.org/10.3133/sir20255081 - USGS, Status and understanding of groundwater quality in the San Joaquin Valley Kern County subbasin domestic-supply aquifer study unit, 2022, SIR 2026-5012 (19 May 2026). https://doi.org/10.3133/sir20265012 - USGS, Comparing domestic and public-supply groundwater quality in the northern San Joaquin Valley, 2019, SIR 2023-5049 (5 June 2023). https://doi.org/10.3133/sir20235049 - Crincoli KR, Huling SG, Chemosphere 330:138648 (2023). https://doi.org/10.1016/j.chemosphere.2023.138648 - Padula AM et al., Environ Epidemiol 5(2):e149 (2021). https://doi.org/10.1097/EE9.0000000000000149

Peer-reviewed studies: DBCP workers, families and cancer - Whorton D et al., Lancet 2:1259–61 (17 Dec 1977). https://doi.org/10.1016/s0140-6736(77)92665-4 - Whorton D et al., J Occup Med 21:161–6 (1979). https://pubmed.ncbi.nlm.nih.gov/556420/ - Goldsmith JR, Potashnik G, Israeli R, Arch Environ Health 39:85–9 (1984). https://doi.org/10.1080/00039896.1984.10545840 - Potashnik G, Goldsmith J, Insler V, Andrologia 16:213–8 (1984). https://doi.org/10.1111/j.1439-0272.1984.tb00266.x - Eaton M et al., J Occup Med 28:1145–50 (1986). https://pubmed.ncbi.nlm.nih.gov/3097279/ - Potashnik G, Yanai-Inbar I, Fertil Steril 47:317–23 (1987). https://doi.org/10.1016/s0015-0282(16)50012-0 - Potashnik G, Phillip M, Andrologia 20:90–4 (1988). https://doi.org/10.1111/j.1439-0272.1988.tb02374.x - Whorton MD et al., Int Arch Occup Environ Health 61:403–7 (1989). https://doi.org/10.1007/BF00381032 - Wong O et al., Br J Ind Med 46:521–8 (1989). https://doi.org/10.1136/oem.46.8.521 - Thrupp LA, Int J Health Serv 21:731–57 (1991). https://doi.org/10.2190/25B9-QFMV-Y28P-L736 - Olsen GW et al., Am J Ind Med 28:399–410 (1995). https://doi.org/10.1002/ajim.4700280309 - Potashnik G, Porath A, J Occup Environ Med 37:1287–92 (1995). https://doi.org/10.1097/00043764-199511000-00007 - Wesseling C et al., Int J Epidemiol 25:1125–31 (1996). https://doi.org/10.1093/ije/25.6.1125 - Goldsmith JR, Ann N Y Acad Sci 837:300–6 (1997). https://doi.org/10.1111/j.1749-6632.1997.tb56882.x - Slutsky M, Levin JL, Levy BS, Int J Occup Environ Health 5:116–22 (1999). https://doi.org/10.1179/oeh.1999.5.2.116 - Teitelbaum DT, Int J Occup Environ Health 5:122–6 (1999). https://doi.org/10.1179/oeh.1999.5.2.122 - Siegel CS, Siegel DS, Int J Occup Environ Health 5:127–35 (1999). https://doi.org/10.1179/oeh.1999.5.2.127 - Meistrich ML et al., Reprod Toxicol 17:263–71 (2003). https://doi.org/10.1016/s0890-6238(03)00007-8 - Meistrich ML et al., Toxicol Sci 76:418–26 (2003). https://doi.org/10.1093/toxsci/kfg237 - Clark HA, Snedeker SM, J Environ Sci Health C 23:215–60 (2005). https://doi.org/10.1080/10590500500234996 - Hofmann J et al., Int J Occup Environ Health 12:321–8 (2006). https://doi.org/10.1179/oeh.2006.12.4.321 - Terrell ML, Hartnett KP, Marcus M, Emerg Health Threats J 4:7109 (2011). https://doi.org/10.3402/ehtj.v4i0.7109 - Ye L, Su ZJ, Ge RS, Molecules 16:9983–10001 (2011). https://doi.org/10.3390/molecules16129983 - Boix V, Bohme SR, Int J Occup Environ Health 18:154–61 (2012). https://doi.org/10.1179/1077352512Z.00000000010

Peer-reviewed studies: other reproductive toxicants and history - Cannon SB et al., Am J Epidemiol 107:529–37 (1978). https://doi.org/10.1093/oxfordjournals.aje.a112572 - Reich MR, Spong JK, Int J Health Serv 13:227–46 (1983). https://doi.org/10.2190/UN1H-RH1N-H09G-CRL5 - Schrag SD, Dixon RL, Annu Rev Pharmacol Toxicol 25:567–92 (1985). https://doi.org/10.1146/annurev.pa.25.040185.003031 - Collins TF, Curr Pharm Des 12:1449–65 (2006). https://doi.org/10.2174/138161206776389813 - Schrader SM, Marlow KL, Asian J Androl 16:23–30 (2014). https://doi.org/10.4103/1008-682X.122352

Peer-reviewed studies: testing methods, endocrine disruptors and trends - Lamb JC et al., Regul Toxicol Pharmacol 69:22–40 (2014). https://doi.org/10.1016/j.yrtph.2014.02.002 - Saghir SA, Regul Toxicol Pharmacol 72:423–8 (2015). https://doi.org/10.1016/j.yrtph.2015.05.009 - Bergman Å et al., Regul Toxicol Pharmacol 73:1007–17 (2015). https://doi.org/10.1016/j.yrtph.2015.07.026 - Gore AC et al., Endocr Rev 36:593–602 (2015). https://doi.org/10.1210/er.2015-1093 - Smith MT et al., Environ Health Perspect 124:713–21 (2016). https://doi.org/10.1289/ehp.1509912 - Levine H et al., Hum Reprod Update 23:646–59 (2017). https://doi.org/10.1093/humupd/dmx022 - Gurney JK et al., Eur Urol 76:615–23 (2019). https://doi.org/10.1016/j.eururo.2019.07.002 - Heringa MB et al., Regul Toxicol Pharmacol 114:104659 (2020). https://doi.org/10.1016/j.yrtph.2020.104659 - Boulicault M et al., Hum Fertil 25:888–902 (2022). https://doi.org/10.1080/14647273.2021.1917778 - Levine H et al., Hum Reprod Update 29:157–76 (2023). https://doi.org/10.1093/humupd/dmac035 - Cipriani S et al., Andrology 11:997–1008 (2023). https://doi.org/10.1111/andr.13396 - Luo X et al., J Assist Reprod Genet 40:1807–16 (2023). https://doi.org/10.1007/s10815-023-02859-z - Nolan C et al., Andrology 14:1164–71 (2026). https://doi.org/10.1111/andr.70193